A systematic review showed that serum elastin peptides (SEP) and plasmin-antiplasmin (PAP) complexes have the strongest association with AAA, and matrix-degrading metalloproteinase 9 (MMP9) and interferon-gamma (INF-γ) are promising for use in clinical applications (Urbonavicius et al., 2008). This evidence concerns the gene MMP9 and triple-A syndrome.